Nkarta appoints Alyssa Levin as CFO and Business Officer effective July 1

Nkarta, Inc.

Annual base salary of $450k, sign-on bonus of $20k, and a stock option for 442,400 shares.
Option vests 25% on July 1, 2024, then monthly over 36 months; exercise price = June 30 closing.
Levin previously CFO at ViaCyte (acquired by Vertex), Tentarix, and Bird Rock Bio.
Target annual incentive bonus set at 40% of base salary.
Company is developing engineered NK cell therapies for cancer (NKX101, NKX019).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alyssa Levin

Chief Financial and Business Officer

NKTX · Nkarta, Inc.

Effective: 2023-07-01
Filed: July 5, 2023, 7:59 PM ET

On June 29, 2023, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Alyssa Levin as the Company’s Chief Financial and Business Officer and the principal financial and accounting officer, effective July 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alyssa Levin was appointed as Chief Financial and Business Officer at Nkarta, Inc..

Action: appointed
Role: Chief Financial and Business Officer

Exact text from the filing

On June 29, 2023, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Alyssa Levin as the Company’s Chief Financial and Business Officer and the principal financial and accounting officer, effective July 1, 2023.

View on SEC.gov

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-031624

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.